Study summary
For tumors without the BRAF change, lenvatinib plus pembrolizumab gave a median of 13 months
13months median survival, against about 3 months with lenvatinib alone historically
What was tested
Lenvatinib, a targeted pill, with pembrolizumab, an immunotherapy, in anaplastic thyroid cancer without the BRAF change that had already spread. No comparison group.
What they found
- Median survival was 13 months and the cancer was held back for a median of 5.4 months.
- Tumors shrank in 36%, including one complete response.
- All patients had distant spread when they started.
What it means
Offers a real option for the roughly 60% of people whose tumors lack the BRAF change.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.